首页> 美国卫生研究院文献>PLoS Pathogens >The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney
【2h】

The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney

机译:激肽释放酶-激肽系统:肾脏中IL-17驱动的抗Candida免疫的新型介体。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The incidence of life-threatening disseminated Candida albicans infections is increasing in hospitalized patients, with fatalities as high as 60%. Death from disseminated candidiasis in a significant percentage of cases is due to fungal invasion of the kidney, leading to renal failure. Treatment of candidiasis is hampered by drug toxicity, the emergence of antifungal drug resistance and lack of vaccines against fungal pathogens. IL-17 is a key mediator of defense against candidiasis. The underlying mechanisms of IL-17-mediated renal immunity have so far been assumed to occur solely through the regulation of antimicrobial mechanisms, particularly activation of neutrophils. Here, we identify an unexpected role for IL-17 in inducing the Kallikrein (Klk)-Kinin System (KKS) in C. albicans-infected kidney, and we show that the KKS provides significant renal protection in candidiasis. Microarray data indicated that Klk1 was upregulated in infected kidney in an IL-17-dependent manner. Overexpression of Klk1 or treatment with bradykinin rescued IL-17RA-/- mice from candidiasis. Therapeutic manipulation of IL-17-KKS pathways restored renal function and prolonged survival by preventing apoptosis of renal cells following C. albicans infection. Furthermore, combining a minimally effective dose of fluconazole with bradykinin markedly improved survival compared to either drug alone. These results indicate that IL-17 not only limits fungal growth in the kidney, but also prevents renal tissue damage and preserves kidney function during disseminated candidiasis through the KKS. Since drugs targeting the KKS are approved clinically, these findings offer potential avenues for the treatment of this fatal nosocomial infection.
机译:住院患者中威胁生命的传播性白色念珠菌感染的发生率正在增加,死亡率高达60%。在很大一部分病例中,传播的念珠菌病导致的死亡是由于肾脏的真菌入侵,导致肾功能衰竭。念珠菌病的治疗受到药物毒性,抗真菌药物耐药性的出现以及缺乏针对真菌病原体的疫苗的阻碍。 IL-17是抵抗念珠菌病的关键介质。迄今为止,已经假定IL-17介导的肾脏免疫的潜在机制仅通过调节抗微生物机制,特别是中性粒细胞的活化而发生。在这里,我们确定了IL-17在白色念珠菌感染的肾脏中诱导激肽释放酶(Klk)-激肽系统(KKS)的意外作用,我们证明了KKS在念珠菌病中提供了重要的肾脏保护作用。微阵列数据表明,Klk1在感染的肾脏中以IL-17依赖性方式上调。 Klk1的过表达或缓激肽治疗可从念珠菌病中拯救出IL-17RA -/-小鼠。 IL-17-KKS途径的治疗性操作可通过预防白色念珠菌感染后肾细胞凋亡来恢复肾功能并延长生存期。此外,与单独使用任一药物相比,将最小有效剂量的氟康唑与缓激肽相结合可显着提高生存率。这些结果表明,IL-17不仅限制肾脏中真菌的生长,而且还可以预防肾脏组织的损害,并在通过KKS传播念珠菌病期间保留肾脏功能。由于靶向KKS的药物已获得临床批准,因此这些发现为治疗这种致命的医院内感染提供了可能的途径。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号